Avanir Pharmaceuticals' CEO Discusses F4Q12 Results – Earnings Call Transcript
Avanir Pharmaceuticals' CEO Discusses F4Q12 Results – Earnings Call Transcript
Filed under: drug treatment news 2011
We reported total net revenue for the fourth fiscal quarter of 2012 of $ 13.5 million, as compared to $ 4.8 million for the comparable period in fiscal 2011, a year over year growth of over 180%. For the fourth fiscal quarter of 2012, we reported a …
Read more on Seeking Alpha
Inspiration Biopharmaceuticals Highlights Positive Interim Data on its Two …
Filed under: drug treatment news 2011
Inspiration‚Äôs OBI-1 investigational drug met the primary endpoint of providing effective or partially effective treatment of serious bleeding in 16 subjects with acquired hemophilia A based on the investigator‚Äôs assessment of response to treatment …
Read more on PharmiWeb.com (press release)
Results From Gentium's Treatment IND for Defibrotide Presented at the …
Filed under: drug treatment news 2011
The interim analysis was based on 333 patients with severe veno-occlusive disease (sVOD) and multi-organ failure (MOF), enrolled between December 2007 and September 2011 at 68 centers across the United States. 305 patients had … Gentium S.p.A …
Read more on MarketWatch (press release)
ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual …
Filed under: drug treatment news 2011
ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis. ACADIA also has … These statements include but are not limited to statements …
Read more on DailyFinance